Investors



  • FOR INFORMATION ON
    REPORTING CHANGES AND
    REVISED REVENUE GUIDANCE click here.


  • FOR GIVEN IMAGING
    ACQUISITION INFORMATION, click here.


  • FOR 2013 INVESTOR DAY MATERIALS,
    click here.


  • For Pharmaceuticals
    spin-off information,
    click here.


  • For tax basis information
    due to the Mallinckrodt spin,
    click here.


RSS Content

Covidien Announces New Evidence that Demonstrates Clinical Efficacy of VNUS ClosureFAST(TM) Catheter
Multicenter Study Results Presented at 37th Annual VEITH Symposium

NEW YORK, Nov 17, 2010 (BUSINESS WIRE) -- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter study using the VNUS ClosureFAST(TM) catheter, demonstrated clinical efficacy and improvement in quality of life for patients. The ClosureFAST catheter is an endovenous radiofrequency (RF) ablation catheter designed to heat and close diseased veins, the major underlying cause of varicose veins.

The results were presented at the American College of Phlebology's 24th Annual Congress in Orlando, Florida on November 5, and here today at the 37th Annual VEITH Symposium on Vascular and Endovascular Issues.

Alan Dietzek, M.D., Chief of Vascular Surgery and the Linda and Stephen R. Cohen Chair in Vascular Surgery at Danbury Hospital in Connecticut, presented three-year follow-up results of patients treated with the ClosureFAST catheter from a study conducted at 13 centers in the U.S. and Europe. Two-hundred sixty-seven greater saphenous veins were evaluated at the follow-up and demonstrated a 93% occlusion rate using Kaplan-Meier analysis.

In addition to clinical efficacy, the study has shown a venous clinical severity score reduction at three-year follow up, which indicates an improvement in patients' relief of symptoms, such as pain or inflammation, from the baseline score at time of treatment.

These results were consistent with those presented this month for the seven European study sites by Professor Thomas M. Proebstle, M.D., PhD, of the Department of Dermatology, University of Mainz, Germany, and the University of Pécs, Hungary, in his presentation titled, "Three Year Follow-Up After Radiofrequency Segmental Thermal Ablation of Great Saphenous Veins." The European study was presented at the American College of Phlebology.

"These study results continue to support and strengthen clinicians' confidence in the ClosureFAST technology and its effectiveness in treating millions of venous insufficiency patients who suffer from varicose veins," said Joe Woody, President, Vascular Therapies, Covidien.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

SOURCE: Covidien

Vascular Therapies
Rachel Bloom Baglin, 508-261-6651
Vice President, Communications
rachel.bloombaglin@covidien.com
or
Covidien
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Cole Lannum, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Brian Nameth, 508-452-4363
Director
Investor Relations
brian.nameth@covidien.com

Stock Quote

COV (Common Stock)
ExchangeNYSE
(US Dollar)
Price$69.86
Change (%) Stock is Up 0.02
 (0.03%)
Volume1,996,576
As of 04/17/14 4:07 p.m. ET
Minimum 20 minute delay
Refresh quote

Tool Kit

Printer Friendly Version    Printer-friendly version
E-mail this page   E-mail this page
RSS    RSS Feeds
E-mail Alerts Receive E-mail Alerts
View contacts     View contacts